Latigo Biotherapeutics Inc. (NASDAQ: LTGO) Stock Competitors & Peer Comparison

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, RPRX has a market cap of 25.1B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while RPRX trades at $56.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas RPRX's P/E ratio is 10.78. In terms of profitability, LTGO's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, LTGO is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check RPRX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CORT has a market cap of 12.7B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CORT trades at $117.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CORT's P/E ratio is 336.57. In terms of profitability, LTGO's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, LTGO is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CORT's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas WBA's P/E ratio is -1.64. In terms of profitability, LTGO's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, LTGO is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check WBA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while KNSA trades at $78.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas KNSA's P/E ratio is 80.96. In terms of profitability, LTGO's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, LTGO is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check KNSA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, LQDA has a market cap of 2.4B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while LQDA trades at $26.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas LQDA's P/E ratio is 19.57. In terms of profitability, LTGO's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, LTGO is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LQDA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while PBH trades at $48.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas PBH's P/E ratio is 10.98. In terms of profitability, LTGO's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, LTGO is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PBH's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas HROWL's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, LTGO is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas HROWM's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, LTGO is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWM's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, HELP has a market cap of 650.8M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while HELP trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas HELP's P/E ratio is -2.52. In terms of profitability, LTGO's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, LTGO is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check HELP's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas SVA's P/E ratio is -5.68. In terms of profitability, LTGO's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, LTGO is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SVA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CUVL has a market cap of 275.6M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CUVL trades at $5.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CUVL's P/E ratio is 11.79. In terms of profitability, LTGO's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CUVL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CELG-RI has a market cap of 241M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CELG-RI's ROE of +0.47%. Regarding short-term risk, LTGO is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CELG-RI's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while HITI trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas HITI's P/E ratio is -9.53. In terms of profitability, LTGO's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, LTGO is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HITI's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, ETRA has a market cap of 182.6M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while ETRA trades at $8.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas ETRA's P/E ratio is -3.25. In terms of profitability, LTGO's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, LTGO is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ETRA's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, TRXB has a market cap of 113.3M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while TRXB trades at $13.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas TRXB's P/E ratio is -5.51. In terms of profitability, LTGO's ROE is N/A, compared to TRXB's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check TRXB's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CTOR has a market cap of 71.6M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CTOR trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CTOR's P/E ratio is -1.64. In terms of profitability, LTGO's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, LTGO is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check CTOR's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas ATLN's P/E ratio is -0.68. In terms of profitability, LTGO's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, LTGO is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ATLN's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, RTSN has a market cap of 44.7M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while RTSN trades at $11.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas RTSN's P/E ratio is -4.57. In terms of profitability, LTGO's ROE is N/A, compared to RTSN's ROE of N/A. Regarding short-term risk, LTGO is less volatile compared to RTSN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check RTSN's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas RAD's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, LTGO is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check RAD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas GLTO's P/E ratio is -1.78. In terms of profitability, LTGO's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, LTGO is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check GLTO's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, NSRX has a market cap of 27.8M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while NSRX trades at $3.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas NSRX's P/E ratio is -4.49. In terms of profitability, LTGO's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, LTGO is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check NSRX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, SCYX has a market cap of 25.1M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while SCYX trades at $3.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas SCYX's P/E ratio is -1.17. In terms of profitability, LTGO's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, LTGO is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SCYX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, COSM has a market cap of 20.8M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while COSM trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas COSM's P/E ratio is -0.52. In terms of profitability, LTGO's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, LTGO is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check COSM's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CNSY has a market cap of 12M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CNSY trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CNSY's P/E ratio is -0.41. In terms of profitability, LTGO's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, LTGO is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check CNSY's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, BFRI has a market cap of 11.4M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while BFRI trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas BFRI's P/E ratio is -1.62. In terms of profitability, LTGO's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, LTGO is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check BFRI's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CJJD's P/E ratio is -0.46. In terms of profitability, LTGO's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, LTGO is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CJJD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas SSY's P/E ratio is -2.86. In terms of profitability, LTGO's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, LTGO is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check SSY's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while SCNX trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas SCNX's P/E ratio is -1.54. In terms of profitability, LTGO's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, LTGO is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check SCNX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, BGMS has a market cap of 5.1M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while BGMS trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas BGMS's P/E ratio is -0.26. In terms of profitability, LTGO's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, LTGO is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check BGMS's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, POM has a market cap of 4.7M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while POM trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas POM's P/E ratio is -0.12. In terms of profitability, LTGO's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, LTGO is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check POM's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, EOCN has a market cap of 3.3M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while EOCN trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas EOCN's P/E ratio is -0.23. In terms of profitability, LTGO's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, LTGO is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check EOCN's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, BFRIW has a market cap of 3.2M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while BFRIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, LTGO's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, LTGO is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BFRIW's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas MDVL's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, LTGO is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check MDVL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, PAVS has a market cap of 2.9M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while PAVS trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas PAVS's P/E ratio is -0.04. In terms of profitability, LTGO's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, LTGO is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PAVS's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas ATNFW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, LTGO is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ATNFW's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, LTGO's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, LTGO is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMSP's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas AZNH's P/E ratio is 38.35. In terms of profitability, LTGO's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check AZNH's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, LTGO's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, LTGO is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LFLYW's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, PRPH has a market cap of 119.1K. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas PRPH's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, LTGO is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check PRPH's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, CPD has a market cap of 0. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas CPD's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CPD's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, OREX has a market cap of 0. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas OREX's P/E ratio is -0.14. In terms of profitability, LTGO's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, LTGO is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check OREX's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, POZN has a market cap of 0. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas POZN's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, LTGO is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check POZN's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas IPXL's P/E ratio is -10.11. In terms of profitability, LTGO's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, LTGO is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check IPXL's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas SHPG's P/E ratio is 11.35. In terms of profitability, LTGO's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, LTGO is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SHPG's competition here

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LTGO stands at 945M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, LTGO is priced at $15.71 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LTGO currently has a P/E ratio of -6.23, whereas ESRX's P/E ratio is 10.69. In terms of profitability, LTGO's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, LTGO is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ESRX's competition here